
Wegovy Nausea: Why It Happens and What Helps
Nausea hit 44% of adults on Wegovy 2.4 mg vs 16% on placebo. Why it happens, 7.2 mg and pill data, what helps, dose options and red-flag symptoms.
Written by Diana Gangan. Updated November 17, 2026.
Nausea is the most common side effect of Wegovy: in the clinical trials behind the FDA label, 44% of adults on the 2.4 mg injection reported nausea, compared with 16% on placebo (a dummy treatment). It happens mostly while the dose is being increased, and for most people it is temporary; Novo Nordisk says nausea was generally transient and usually did not lead people to stop treatment permanently. The higher 7.2 mg dose (Wegovy HD) caused nausea in 39% of people in its trial, and the label says the Wegovy pill causes side effects similar to the injection. What helps most is eating smaller meals slowly, stopping when you feel full, drinking enough fluids and, if nausea is hard to tolerate, asking your prescriber about the label's option to delay the next dose increase. This guide explains why Wegovy causes nausea, when it is worst, what helps, and which symptoms mean you should call your doctor, using the US label as of November 2026.
Wegovy Nausea: The Short Answer
- 1How common: 44% on Wegovy 2.4 mg vs 16% on placebo; 39% on 7.2 mg in its trial.
- 2When: digestive side effects were most often reported during dose escalation.
- 3Duration: generally transient, per Novo Nordisk; the label gives no average duration.
- 4What helps: smaller, slower meals, stopping when full, fluids and fresh air.
- 5Dose options: your prescriber can delay a dose increase by 4 weeks or lower 2.4 mg to 1.7 mg.
- 6Red flags: severe belly pain spreading to the back, signs of gallbladder problems, or being unable to keep fluids down.
How Common Is Nausea on Wegovy?
Very common. In the adult trials summarized in the Wegovy label, nausea affected 44% of people taking the 2.4 mg injection and 16% of people taking placebo. Vomiting affected 24% versus 6% (the label's narrative text gives 25%), diarrhea 30% versus 16% and constipation 24% versus 11%.
Most people stay on treatment. In adults, 4.3% stopped Wegovy 2.4 mg because of digestive side effects, compared with 0.7% on placebo. Severe digestive reactions were reported in 4.1% of people on the injection and 0.9% on placebo. For the related problem of constipation, see Wegovy constipation.
Digestive side effects in the Wegovy label trials
Wegovy 2.4 mg injection (adults)
44%
24%
30%
24%
4.3%
Placebo (2.4 mg trials)
16%
6%
16%
11%
0.7%
Wegovy 7.2 mg (STEP UP)
39%
22%
Not listed
20%
3%
Wegovy 2.4 mg (STEP UP)
35%
Not given
Not listed
Not given
3%
Placebo (STEP UP)
13%
Not given
Not listed
Not given
0.3%
Wegovy tablets 25 mg
Similar to injection (no separate US figure)
Similar
Similar
Similar
3.4% (vs 2% placebo)
Why Does Wegovy Cause Nausea?
Wegovy contains semaglutide, a GLP-1 receptor agonist. It copies a natural gut hormone, GLP-1, that helps control appetite and fullness. GLP-1 medicines act on the digestive system and slow how quickly food leaves the stomach, which is part of why people feel full sooner and eat less. The same effects can leave you feeling queasy, especially after a large or fatty meal, or when your body is adjusting to a new, higher dose. Our explainer on what Wegovy does covers how it works in more detail.
When Does Wegovy Nausea Start, and When Is It Worst?
The label says digestive side effects were most frequently reported during dose escalation, the period when the dose is stepped up every four weeks. For the injection, the label's schedule is 0.25 mg in weeks 1 to 4, 0.5 mg in weeks 5 to 8, 1 mg in weeks 9 to 12 and 1.7 mg in weeks 13 to 16, with the maintenance dose from week 17. So the weeks after starting and after each dose step are when nausea is most likely. The full schedule is explained in our Wegovy dosing schedule guide.
The label does not give a typical start day or how many days nausea lasts after each injection. Some websites quote specific averages, but we could not find a reliable source for them, so we do not repeat them here.
Is Nausea Worse on Wegovy 7.2 mg?
A little more common, but not dramatically. The FDA approved the 7.2 mg dose, marketed as Wegovy HD, on March 19, 2026. In the STEP UP trial reported in the label, nausea affected 39% of people on 7.2 mg, 35% on 2.4 mg and 13% on placebo. Vomiting affected 22% and constipation 20% of people on 7.2 mg. About 3% of people on either 7.2 mg or 2.4 mg stopped because of digestive side effects, compared with 0.3% on placebo.
Importantly, the label allows 7.2 mg only after a person has tolerated 2.4 mg for at least 4 weeks, so people move up only once they have adjusted to the standard dose. More is in our Wegovy HD 7.2 mg guide.
Does the Wegovy Pill Cause Less Nausea?
Not according to the label. The Wegovy pill was reported as FDA-approved in December 2025. The US label says the types and frequency of common side effects with the 25 mg tablet were similar to those seen with the injection, and it does not give a separate nausea percentage. In the OASIS 4 trial of the pill, published in the New England Journal of Medicine in 2025, digestive side effects were reported in 74% of people on the pill and 42% on placebo; 7% versus 6% stopped because of side effects of any kind. In the label, 3.4% of pill users stopped because of digestive side effects, compared with 2% on placebo.
The pill also has its own escalation: 1.5 mg for days 1 to 30, 4 mg for days 31 to 60, 9 mg for days 61 to 90 and 25 mg from day 91. It must be taken on an empty stomach with up to 4 ounces of water, waiting at least 30 minutes before eating or drinking. Our guides on Wegovy pill side effects and how to take the Wegovy pill go into more detail.
How Long Does Wegovy Nausea Last?
For most people, not long, but there is no official number. Novo Nordisk's patient materials say nausea was generally transient and that most occurrences did not lead to permanent discontinuation. The label links digestive side effects mainly to dose escalation rather than to the maintenance phase. If nausea does not settle, the label's Medication Guide says to tell your healthcare provider right away about nausea, vomiting or diarrhea that does not go away.
What Helps Wegovy Nausea?
Novo Nordisk suggests eating more slowly, eating foods that contain water and going outside for fresh air, and asks whether frequent small meals could help. Practical steps that follow from those suggestions include:
- 1Eat smaller portions, more often, instead of three large meals
- 2Eat slowly and stop as soon as you feel full, even if food is left
- 3Choose water-rich foods such as soups, fruit and vegetables
- 4Sip fluids through the day; the Medication Guide advises drinking fluids to avoid dehydration
- 5Step outside for fresh air when a wave of nausea hits
- 6If you drink, read our guide to Wegovy and alcohol first
Some people also try ginger tea or plain crackers. These are not mentioned in the label and have not been tested specifically for Wegovy nausea, so treat them as optional comfort measures. Do not start an anti-nausea medicine on your own; if you need one, your prescriber can recommend an option that suits you. Feeling run down at the same time is also common, as discussed in does Wegovy make you tired.
Can I Stay on a Lower Dose if Nausea Doesn't Stop?
Possibly, and the label gives your prescriber several options. If you do not tolerate a dose during escalation, the label says to consider delaying the next dose increase for 4 weeks. If the 2.4 mg maintenance dose is not tolerated, it can be lowered to 1.7 mg once weekly. For the pill, the label says to consider delaying escalation if a dose is not tolerated, and if 25 mg is not tolerated, to consider switching to the 1.7 mg injection. These are clinical decisions, so do not change your dose without talking to your prescriber. Our article on staying on a low dose of Wegovy discusses the trade-offs.
When Is Wegovy Nausea a Red Flag?
Most nausea is a nuisance, not a danger. But the label warns about several serious problems that can start with stomach symptoms. Pancreatitis (inflammation of the pancreas) can cause severe abdominal pain that may spread to the back, with or without vomiting; if it is suspected, the label says to stop Wegovy and contact your provider. Gallstones were reported in 1.6% of people on the injection and 2.5% on the tablets, compared with 0.7% and 1% on placebo. Acute kidney injury has been reported, mostly in people whose digestive side effects led to dehydration.
Stomach symptoms that need prompt attention
Severe belly pain that may spread to the back, with or without vomiting
Pancreatitis
Stop Wegovy and call your provider; seek urgent care
Pain in the upper right belly, fever, yellow skin or eyes
Gallbladder problems
Call your provider
Cannot keep fluids down, passing little urine, dizziness
Dehydration and possible kidney injury
Call your provider promptly; drink fluids
Nausea, vomiting or diarrhea that does not go away
Ongoing GI side effects
Tell your provider right away
Longer-term safety questions are covered in GLP-1 long-term side effects.
When to Talk to Your Doctor
- 1Nausea, vomiting or diarrhea that does not go away, or that stops you eating or drinking
- 2Signs of dehydration, such as very little urine, dark urine or dizziness when standing
- 3Severe stomach pain, especially if it spreads to your back (seek urgent care)
- 4Upper right belly pain, fever or yellowing of the skin or eyes
- 5Nausea that makes you want to skip or stop doses
- 6Before moving up to the next dose if you are still struggling with the current one
What to Do Next: Questions to Ask Your Doctor
- 1Should we delay my next dose increase by 4 weeks?
- 2If 2.4 mg is hard to tolerate, would 1.7 mg be right for me?
- 3Is an anti-nausea medicine appropriate for me, and which one?
- 4Should my kidney function be checked while I am increasing the dose?
- 5If I switch between the pill and the injection, what should I expect for side effects?
The Bottom Line
Nausea is the most common Wegovy side effect, affecting 44% of adults on 2.4 mg and 39% on 7.2 mg in the trials behind the label, and the pill's side effects are described as similar. It is most likely while the dose is being increased and is usually temporary, though the label gives no average duration. Smaller, slower meals, stopping when full, fluids and fresh air can help, and your prescriber can delay a dose increase or lower the maintenance dose if needed. Severe belly pain, signs of gallbladder problems or being unable to keep fluids down are reasons to contact your provider promptly.
FAQ
The label does not give an average duration. Novo Nordisk says nausea was generally transient, and digestive side effects were most common during dose increases. Tell your provider if nausea does not go away.
For most people it does. Most cases of nausea in the trials did not lead to stopping treatment permanently, and only 4.3% of adults on 2.4 mg stopped because of digestive side effects.
Eating more slowly, smaller and more frequent meals, water-rich foods, fluids and fresh air. Your prescriber can also delay a dose increase by 4 weeks if a dose is not tolerated.
Slightly. In the STEP UP trial, nausea affected 39% of people on 7.2 mg, 35% on 2.4 mg and 13% on placebo.
Yes. The US label says the pill's common side effects were similar to the injection's. In the OASIS 4 trial, digestive side effects occurred in 74% of people on the pill and 42% on placebo.
Call if vomiting does not go away, if you cannot keep fluids down or have signs of dehydration, or if it comes with severe belly pain that may spread to your back.
Sources
- 1Novo Nordisk. WEGOVY (semaglutide) injection and tablets, prescribing information and Medication Guide (revised 06/2026), U.S. Food and Drug Administration, 2026
- 2Novo Nordisk. WEGOVY (semaglutide) injection and tablets, prescribing information (revised 05/2026), U.S. Food and Drug Administration, 2026
- 3Wharton S, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4 journal scan), American College of Cardiology (N Engl J Med 2025;393:1077-1087), 2025
- 4FDA OK's higher dose Wegovy injection for weight loss, Epocrates, 2026
- 5Wegovy pill receives FDA approval as first oral GLP-1 for weight loss, Drug Topics, 2025
- 6Novo Nordisk. Keeping an eye on common side effects, Wegovy.com
This article is general information based on the FDA-approved Wegovy label and published trial data, and it is not a substitute for advice from your prescriber. The trials cited were sponsored by Novo Nordisk, which makes Wegovy; manufacturer patient materials cited here are company materials.

Diana Gangan
Author
Comments (0)
Be the first to comment on this article.




